

CURRICULUM VITAE

NAME: Anne Elizabeth Cress

EDUCATION:

- 1972-1975 University of Arizona, Tucson, Arizona,
B.S., Microbiology/Chemistry
- 1976-1980 University of Arizona, Tucson, Arizona,
Ph.D., Biochemistry/Molecular Biology
Director: Eugene W. Gerner, Ph.D.
- 1980-1981 Postdoctoral Training; University of Arizona, Radiation Oncology
DNA Damage and Carcinogenesis.
Director: G. Tim Bowden, Ph.D.
- 1986-1987 Visiting Scholar, Stanford University, Stanford, CA.
DNA Polymerase-primase in *Drosophila Melanogaster* During early Embryonic Development.
Director: I. Robert Lehman, Ph.D.
- 1997 Sabbatical Leave, Drug Development and Design Center, University of Queensland, Brisbane,
Australia
Homology Model of the $\alpha 6$ Integrin and Candidate Peptide Antagonists
Director: Ross Brinkworth, Ph.D.
- 2006 Sabbatical Leave, Netherlands Cancer Institute, Antoni van Leeuwenhoek University,
Amsterdam, Holland.
The Hemidesmosome as a Tumor Suppressor Proteome
Director: Arnoud Sonnenberg, Ph.D.

STATEMENT OF MAJOR RESEARCH INTERESTS:

My major fields of interest include the regulation of cell adhesion proteins and cellular damage responses. Specifically, I am studying the role of cellular adhesion mediated by integrin molecules in human cancer metastasis and recurrence. Current work indicates that blocking integrin function can prevent bone metastases. The integrin molecules are transmembrane proteins which participate in organizing the cytoskeleton, modifying cellular adhesion and transmitting signals which influence cellular damage responses. Cell adhesion mediated drug resistance and radiation resistance, as discovered by our group, are major barriers to effective cancer treatment.

PROFESSIONAL EXPERIENCE:

- 1975 to 1976 Laboratory Medical Technologist, Clinical Pathology Department, University of
Arizona College of Medicine, Tucson, AZ

1980 to 1981	Research Associate, Division of Radiation Oncology, University of Arizona, Tucson, AZ
1981 to 1985	Research Assistant Professor, Division of Radiation Oncology, University of Arizona, Tucson, AZ
1985 to 1989	Assistant Professor, Department of Radiation Oncology, University of Arizona, Tucson, AZ
1990 to 1995	Associate Professor, Radiation Oncology, University of Arizona, Tucson, AZ
1996 to present	Professor, Radiation Oncology, University of Arizona, Tucson, AZ
1999 to present	Professor, Molecular and Cellular Biology, University of Arizona, Tucson, AZ
2000 to 2006	Director, Cancer Metastasis and Signaling Program, Arizona Cancer Center
2003 to present	Professor, Cell Biology and Anatomy, University of Arizona, Tucson, AZ
2003 to 2009	Associate Dean for Research, College of Medicine, University of Arizona, Tucson, AZ
2009 to present	Deputy Dean for Research, College of Medicine, University of Arizona, Tucson, AZ

FELLOWSHIPS, AWARDS AND HONORS:

- 1999 Outstanding Research Investigator Award, Moffitt Cancer Center
- 2005 Founder's Day Award, Arizona Health Sciences Center, University of Arizona
- 2005 Elkin Award for Cancer Biology Research, Emory University
- 2008 Sydney E. Salmon Award, Senior Investigator, Arizona Cancer Center, University of Arizona

TEACHING EXPERIENCE:

A. Formal Courses

1. Spring 1981 - Cancer Biology (Microbiology 398 A) Graduate Course (26 students), 6 lecture hours.
2. Spring 1981 - Radiobiology, Radiation Oncology Residents (4 Students), 10 lecture hours.
3. Fall 1981 - Radiobiology, Radiation Oncology Technologists (3 Students), 4 1/2 lecture hours.
4. Fall 1981 - Radiology 501, Graduate Course (9 Students), 8 lecture hours.
5. Spring 1982 - Molecular and Medical Microbiology 594X, Environmental Carcinogenesis, Graduate Course (12 Students), 3 lecture hours.

6. Fall 1982 - Radiobiology, Radiation Oncology Technologists, (4 Students) and Radiation Oncology Residents (2 Students), 6 lecture hours.
7. Spring 1983 - Cancer Biology, Microbiology 555, Graduate Course (20 Students), 6 lecture hours.
8. Fall 1983 - Radiobiology, Radiation Oncology Technologists (3 Students) and Radiation Oncology Residents (2 Students), 6 lecture hours.
9. Spring 1984 - Molecular and Medical Microbiology 555, Environmental Carcinogenesis, Graduate Course (12 Students), 6 lecture hours.
10. Summer 1984 Radiation Biology for Diagnostic Radiology Residents (5 Students), 2 hours of instruction a week for 8 weeks.
11. Spring 1985 Cancer Biology, MBIM555, Graduate Course (25 Students), 9 lecture hours.
12. Fall, 1987 Developmental Biology, MCB456, Graduate Course (20 Students), 3 lecture hours.
13. Spring 1987 Cancer Biology, MBIM555, Graduate Course (35 Students), 4 lecture hours.
14. Spring 1988 Environmental Carcinogenesis, Microbiology and Immunology 551, Graduate Course (12 Students), 6 lecture hours.
15. Fall 1988, 1990, 1992, 1994 Eukaryotic DNA Replication, (CBIO/MBIM/MCB/BIOC 505), Graduate Course (22 students). **Initiated** the course, organized the course, evaluated the students and gave all the lectures, except for one guest lecture, 45 lecture hours.
16. Spring 1989, 1991 Cancer Biology, Graduate Course (CBIO/MBIM/ANAT 555) organized the course, evaluated the students and gave lectures. (25 students), 14 lecture hours.
17. Spring 1989- Cell Biology, (ANAT/MCB 577), Graduate Course, 3 lecture hours.
18. Spring and Fall, 1986, 1987, 1988, 1989, 1990, 1991, 1992 Cancer Biology Seminar Series, Microbiology and Immunology 596H, **Initiated** and organized the series, recruited speakers and participated, 32 hours/year.
19. Fall 1989, 1991 Independent Study Series, MBIM 899, I meet once weekly for two hours with three students for a total of 6 hours/week. For each student we discuss specific topics using current reviews and scientific articles. Graduate students were from the departments of Biochemistry and Pharmacology.
20. Fall 1989, Molecular Genetics (MBIM 551) Graduate Course, guest lecture, "SV40 DNA Replication".
21. Fall 1996, Freshman Colloquium A&S 195A "Cell Adhesion and Migration".
22. Fall 1996, Tumor Immunology, Graduate Course, MBIM 562 "Invasion and Metastasis of Cancer".
23. Spring 1997, Experimental Therapeutics Graduate Course, (CBIO 555), five lectures, "Radiation Biology and Prostate Cancer Progression".

24. Spring 1997, 1998, 1999, 2000, 2001, 2002, 2003 Clinical Cancer Biology, CBIO 560 Graduate Course, **initiated** and organized the course, evaluated students. Team taught with Drs. Stea (Radiation Oncology), Warneke (Surgery), Dalkin (Surgery), Miller (Medicine) and Nagle (Pathology)
25. Spring 1997, Radiation Biology for Residents, organized the course and evaluated students. Team taught with Dr. Bowden (Radiation Oncology).
26. Fall 1997, 1998, 1999 Lecture, Tumor Immunology, Graduate Course, MBIM 562 “Invasion and Metastasis of Cancer”.
27. Spring, 1999, 2000, 2001, 2002, 2003 Advances in Molecular Medicine, MCB 450, Undergraduate course, **initiated** and organized the course. Team taught with Jennifer Hall, Ph.D. 23 lecture hours, approx. 35 students/semester.
28. Fall 1999, 2009 2 Lectures, Cancer Genetics, Graduate Course, CBIO 589.
29. Fall 2001, Radiobiology/Cancer Biology for Radiation Oncology residents, Lecture “DNA Damage and Repair”.
30. Fall 2001, Molecular and Cellular Cardiovascular Biology, Lectures “Integrins” and “Integrin Signaling”
31. Fall 2003, Radiation Biology, Resident training, lecture.
32. Spring 2004, CBA 577 Principles of Cell Biology, 2 lectures.
33. Fall 2004, Spring and Fall 2005-Present Frontiers in Medical Research Seminar Series CBIO496j/596j (crosslisted in CBA, MCB and MED). **Initiated** and organized course. Each seminar paired researchers in basic and clinical research to highlight the very best in basic and translational research at the University of Arizona that is a sponsored project. Alternatively, data blitz seminars are scheduled and external invited speakers present. Approximately 100 students, faculty, residents, fellows and staff attend the seminars.
34. Fall 2004 to Present. AHSC Frontiers in Medical Research Poster Forum. **Initiated** and organized the first poster forum of its kind at the University of Arizona Health Sciences Center. Approx. 400 faculty and students attend the poster forum.
35. Fall 2005 Radiobiology for the Radiation Oncology residents, “Molecular Mechanisms of DNA Repair”.
36. Spring 2004-present PCOL630a Cellular Communications and Signal Transduction, 2 lectures.
- B. 1977-1978 Teaching Assistant in Medical Biochemistry, Department of Biochemistry, University of Arizona, Tucson.
- C. 1978-1979 Medical Student Tutor in Biochemistry, Department of Biochemistry, University of Arizona, Tucson.
- D. 1981 Lecture, Radiation Oncology for Nurses, Southwestern Radiation Oncology, Ltd. and the College of Nursing, University of Arizona, Tucson.
- E. 1987 Medical Student Enrichment Elective, Radiation Oncology, (10 students) 3 lecture hours.

F. Undergraduate Level Training

(Biochemistry 399H - Honors Independent Study Program)

(Undergraduate Biology Research Program - UBRP), (Summer Research Institute)

1. Rebecca Stanley	Organization of DNA Nucleoids Isolated from Mammalian Cells During DNA Damage and Repair	1982
2. Mary Mazza	Identification of Proteins Involved in IDNA Protein Crosslinks in Irradiated Cells	1983
3. Jose Padilla	Quantitation of Membrane Bound Cholesterol in Thermotolerant Cells	1984
4. Shirley Davis	Whole Mount Electron Microscopy of Nucleoids Isolated from Chinese Hamster Ovary Cells	1985
5. Kamran Aflatoon	Increased Stability of Microfilament Bundles in Chick Embryo Fibroblasts	1988
6. Ben Vanlandingham	Heat Shock Effects on Integrins	1990
7. Megan Lehrkamp	Integrin Expression in Prostate Cancer	1992
8. Saijal Gupta	Inhibition of DNA Initiation and p53 Protein	1994
9. Mike Pennington	Nuclear Localization of p53 Protein	1994, 1995
10. Clint Ludi	Cytokeratin Expression and Drug Resistance	1994, 1995
11. Travis Wheeler	DNA Structural Domains and Radiation Damage	1995
12. John Hau	Integrin $\alpha 6$ Specific Peptides	1997
13. Winnie Mar	Peptides and Cancer	1997
14. Tom Sroka	Adhesion Peptides for Tumor Cells	1998
15. Ian DeRoock	Laminin 5 Adhesion	1998
16. Courtney Lockhart	Summer Research Institute	1999
17. Tom Sroka	Adhesion Peptides for Tumor Cells	1999
18. Michele Roddy	Targeting Human Lung Cancer by Adhesion Peptides	2000
19. James Aguilar	Ionizing Radiation-induced Apoptosis and Cell Adhesion	2000
20. Mike Wu	Radiation Sensitive Antibodies in Human Lymphoma Cells	2000

21. Ryan Cameron	Integrin signaling in cancer	2002-2005
22. Albert Gutierrez	Integrin clipping in T-lymphocyte activation	2003-2005
23. Aaron Lisberg	DNA methylation of cell adhesion genes	2004
24. Melissa Moreno	Minority Health Disparities Research Program, summer	2004
25. Michael Zucarrelli	Expression of laminin 5 in human prostate tissue	2004
26. Tiama Friend	Effective chemical inhibitors on induced cell migration Minority Health Disparities Summer Research Program	2005
27. Edna Cruz	Minority Health Disparities Summer Research Program Cell adhesion mediated radiation resistance.	2007
28. Danyel Wynn	MARC program, Alpha6 integrin regulation in cancer progression	2007-2008
29. Jessica Rheudasil	Women's Cancers/Quality of Life internship, American Cancer Society	2008
30. Oghenevwogaga "Ogaga" Ojameruaye	CURE student	2008
31. Kris Roach	Tumor cells in bone metastasis	2009- 2010
32. Todd Anderson	Tumor cells in bone metastasis	2009- 2011
33. Cynthia Sandoval	MARC program, uPAR and human prostate cancer	2009-2011
34. Bradley Bowman	MARC program, MicroCT analysis of Bone metastasis	2010-2011
35. Stephanie Strautman	UBRP program, Regulation of Integrin A6 Function	2010-2012
36. Harsharon Chopra	UBRP program, Schwann Cells and Cancer Invasion	2010-2012
36. Joshua Gordon	Actin Dynamics and Integrin A6 Function	2011-present
37. Andrea Casillas	Novel Feedback Mechanism of Integrin A6 function	2011-present

G. Medical Student Training

1. Zohreh Kazemi	Isolation of DNA Replication Intermediates in Chinese Hamster Ovary Cells	1987
------------------	--	------

H. Oncology Fellows/Radiation Oncology/Pathology Resident Training

1. William S. Dalton, M.D., Ph.D Dept. of Medicine	Biochemical Characterization of a Drug Resistant Human Myeloma Cell Line	1984
---	---	------

2. Charles Taylor, M.D. Dept. of Medicine	Effect of Hyperthermia on a Doxorubicin Resistant Human Myeloma Cell Line	1987
3. John A. Majda, M.D. Dept. of Radiation Oncology	Early Detection of Human Tumor Metastasis in Bone Marrow Samples	1989
4. John Daller, M.D. Dept. of Surgery	Biochemistry of Regenerating Rat Liver	1989
5. John Anderson, M.D., Ph.D. Dept. of Radiation Oncology	Cytokeratin and Drug Resistance	1996
6. Lisa Heindl, M.D. Dept. of Surgery	Cytokeratin and Drug Resistance	1996
7. Charles Woo, M.D. Dept. of Radiation Oncology	Integrin Expression and Prostate Cancer	1996
8. John Anderson, M.D., Ph.D. Dept. of Radiation Oncology	Integrin Expression and Prostate Cancer	2000-2001
9. Christopher Geffre, M.D., Ph.D. Dept. of Pathology	Non-toxic targeting of ITGA6 prevents Prostate Cancer Progression in Bone	2012-now
10. Amit Algotar, M.D., Ph.D., M.P.H.	DNA damage Response in Prostate Cancer	2012-now

I. Graduate Students

1. James R. Glass	Ph.D. Microbiology & Immunology Polyamine-Mediated Degradation of Ornithine Decarboxylase in Chinese Hamster Ovary Cells (Substituted as major advisor during Dr. Gerner's sabbatical)	1986
2. Vera Francoeur (Major advisor)	M.S. Microbiology & Immunology Characterization of Polyclonal Antibodies Specific for DNA Attachment Proteins	1990
3. Vickie Peck (Major Advisor)	Ph.D. Microbiology & Immunology Purification and Characterization of the DNA Polymerase-Primase from <i>Drosophila melanogaster</i>	1992
4. Pamela Parrish (Major Advisor)	M.S. Pharmacology Identification of Intracellular Proteins Bound by Chemotherapeutic Drugs in Drug Sensitive and Resistant Human Colon Carcinoma Cell Lines	1990
5. Larry Verneti	Ph.D. Pharmacology	1991

(Minor Advisor)	Cyclosporin Modification of Keratin Proteins	
6. Patricia Bauman (Major Advisor)	Ph.D. Pharmacology/Toxicology Cytokeratin and Mitoxantrone Resistance	1994
7. Colette Witkowski (Major Advisor)	Ph.D. Genetics Integrin Genes in Tumor Progression	1995
8. Isaac Rabinovitz (Major Advisor)	Ph.D. Cancer Biology $\alpha 6$ Integrin in Human Prostate Tumors	1995
9. Dorothea von Bredow (Co-Major Advisor with Dr. Ray Nagle)	Ph.D. Cancer Biology Protease and Signaling in Human Prostate Cancer	1997
10. John McCandless (Major Advisor)	M.S. Biology Prostate Tumor Vascularity Analyzed by Confocal Microscopy	1997
11. Tracy Davis (Major Advisor)	M.D., Ph.D. Cancer Biology Alterations of the $\alpha 6\beta 4$ and $\alpha 6\beta 1$ Integrins in Prostate Carcinoma	2001
12. Tom Sroka (Major Advisor)	M.D., Ph.D. Cancer Biology Synthetic Peptide Ligand Mimetics and Tumor Cell Motility	2005
13. Manolis Demetriou (Major Advisor)	Ph.D. Cancer Biology Integrin clipping: A novel adhesion switch?	2004
14. Sangita Pawar (Major Advisor)	Ph.D. Molecular and Cellular Biology Regulation of Integrin Alpha 6 Cleavage	2006
15. Michael Ports (Major Advisor)	Ph.D. Cancer Biology Laterally Associated Proteins Modulate alpha 6 Integrin Cleavage, A Permissive Process Utilized During Cancer Metastasis	2009
16. Apollo Kacsinta (Major Advisor)	Ph.D. Cancer Biology Molecular Effectors of Integrin Alpha 6 Cleavage	2010
17. Cynthia Sandoval (Major Advisor)	Ph.D. Cancer Biology Integrin Laminin Receptors as Metastatic Determinants	Current
18. Lipsa Das	Ph.D. Cancer Biology Integrin Endocytosis and Cancer Invasion	Current

J. Supervisory Committees

1. Peh Yean Cheah (Minor Examiner)	Ph.D. Genetics; Microbiology/Immunology Carcinogenesis by Bile Acids - A Molecular Approach	1989
2. Ti Lin (Major Examiner)	Ph.D. Microbiology/Immunology Drug Resistance in Transformed and Non-Transformed	1990

Rat Fibroblasts

3. Joe Rabinowitz
(Major Examiner) M.S. Microbiology/Immunology 1989
The Autoproteolytic Nature of the *Drosophila melanogaster*
and Human Heat Shock Protein 70 made *in vitro*
4. Vickie Peck
(Major Examiner) Ph.D. Microbiology/Immunology 1992
Purification and Characterization of the DNA Polymerase-
Primase from *Drosophila melanogaster*
5. Pamela Parrish
(Major Examiner) M.S. Pharmacology 1990
Characterization of Drug Resistant Human Breast Tumor Cells
6. Vera Volk
(Major Examiner) M.S. Microbiology/Immunology 1990
Characterization of Polyclonal Antibodies Specific for DNA
Attachment Proteins
7. Larry Verneti
(Minor Examiner) Ph.D. Pharmacology/Toxicology 1991
Cyclosporin Modification of Keratin Proteins
8. Kaya Andrews
(Major Examiner) Ph.D. Microbiology/Immunology 1994
Dominant Transforming Genes in Basal Cell Carcinomas
9. Brandt Schneider
(Major Examiner) Ph.D. Microbiology/Immunology 1994
Tumor Suppressor Genes and Carcinogenesis
10. Dina Millikin
(Major Examiner) M.S. Committee on Genetics 1991
Loss of Tumor Heterozygosity
11. M. Siadat Pajouh
(Major Examiner) Ph.D. Microbiology/Immunology 1990
Transin Gene Expression in Human Tumor Tissue
12. Yi-Wen Chu
(Major Examiner) Ph.D. Cancer Biology 1994
Invasion and Metastasis of Human Melanoma
13. Stephen Rundlett
(Minor Examiner) Ph.D. Molecular and Cellular Biology 1994
Regulation of the Androgen Receptor
14. Jennifer Sweirgel
(Minor Examiner) Ph.D. Molecular and Cellular Biology 1994
15. William Powell
(Major Examiner) Ph.D. Cancer Biology 1994
Proteases and Tumor Cell Invasion
16. Francis Flomerfelt
(Minor Examiner) Ph.D. Molecular and Cellular Biology 1994
17. Alan P. Brown
(Minor Examiner) Ph.D. Pharmacology/Toxicology 1992

18.	H. David Wu (Major Examiner)	MD/Ph.D. Cancer Biology APC Gene and Colorectal Cancer	1996
19.	Jay Hoying (Minor Examiner)	Ph.D. Physiology Cellular Migration	1995
20.	Dorothea von Bredow (Major Examiner)	Ph.D. Cancer Biology Integrin Signaling	1997
21.	Ralph Bernstein (Major Examiner)	Ph.D. Microbiology/Immunology Immunoglobulin Gene Evolution	1996
22.	John McCandless (Major Examiner)	M.S. Biology Prostate Tumor Vascularity Analyzed by Confocal Microscopy	1996
23.	Alan Parrish (Major Examiner)	Ph.D. Pharmacology Prostate Tumor Slices	1997
24.	Russell Klein (Major Examiner)	Ph.D. Cancer Biology Stromal Factors and Prostate Cancer Progression	1998
25.	Jason Damiano (Minor Examiner)	Ph.D. Pharmacology Integrin Expression in Multiple Myeloma	1999
26.	Tracy Davis (Major Examiner)	M.D./Ph.D. Cancer Biology Alterations of the alpha6beta4 and alpha6beta1 integrins in prostate carcinoma	2001
27.	Nhan Tran (Major Examiner)	Ph.D. Cancer Biology Adhesion Receptors in Prostate Cancer	2002
28.	Kameha Kidd (Minor Examiner)	Ph.D. Physiology Vascular Integrins	2002
29.	Weixing Chen (Major Examiner)	Ph.D. Cancer Biology UVB Irradiation and AP-1 Activation	1999
30.	Seongmin Han (Minor Examiner)	Ph.D. Microbiology/Immunology Peptide Substrates for Protein Kinase	2003
31.	David Samuelson (Major Examiner)	Ph.D. Cancer Biology	2001
32.	Ashley Powell (Major Examiner)	Ph.D. Cancer Biology	2002
33.	Kara Nyberg (Minor Examiner)	Ph.D., Molecular and Cellular Biology	2003
34.	Naveen Babbar	Ph.D., Biochemistry	2003

(Minor Examiner)

- | | | |
|--|--|------|
| 35. David Morse
(Minor Examiner) | Ph.D., Biochemistry | 2004 |
| 36. Sangeeta Rojanala
(Major Examiner) | Ph.D., Molecular and Cellular Biology | 2004 |
| 37. Fei Hong
(Minor examiner) | Ph.D., Pharmacology Toxicology | 2005 |
| 38. Heather Handl
(Minor Examiner) | Ph.D., Biochemistry | 2005 |
| 39. Nelson Alexander
(Major Examiner) | Ph.D., Cancer Biology | 2005 |
| 40. Anders Omsland
(Minor Examiner) | Ph.D., Cell Biology and Anatomy | 2005 |
| 41. Ryan Wozniak
(Minor Examiner) | Ph.D., Pharmacology Toxicology | 2006 |
| 42. Dipti Mehta
(Minor Examiner) | Ph.D., Molecular and Cellular Biology | 2006 |
| 43. Meredith C. Henderson
(Major Examiner) | Ph.D., Cancer Biology | 2008 |
| 44. Damian Junk
(Major Examiner) | Ph.D., Cancer Biology | 2008 |
| 45. Saumya VanderWyst | Ph.D. Biomedical Engineering (Minor Advisor) | 2010 |
| 46. Devki Sukhtankar | Ph.D. Cancer Biology (Major Advisor) | 2010 |
| 47. Corinna Wagner, Exchange student, Cancer Biology, Technical University
Munich, Germany, | | 2008 |
| 48. Barbara Viela, graduate student, Brazil, | | 2008 |
| 49. Johannes Gunther, Exchange Student, Cancer Biology, Germany | | 2011 |
| 50. Zyanya Riguer, Summer research Student, Mexico City | | 2011 |

J. High School Students

Summer 1996, Eric Rief, Sir William Osler Fellow
“DNA Damage Response in Prostate Cancer Cells”
Summer 1997, Michael Kim, Sir William Osler Fellow

“Micronuclei in Formation”
Summer 1998, Lily Holmes, Sir William Osler Fellow
“Prostate Cancer Cell Growth After Ionizing Radiation: Effects of Cell-Substratum Interactions”
Summer 1999, Brian Novak, NIH Disadvantaged High School Student Research Program
Summer, 2000, Jennifer Spegal, AHSC MedCamp
Summer, 2004, Hannah King, volunteer for research experience

LOCAL SERVICE ACTIVITIES: (most recent listed first)

Current Service:

Member, UA Cancer Center Director Search, 2012-current

Member, Senior VP for Health Sciences Search Committee, 2012-current

Member, Financial Oversight Committee for UA Cancer Center, 2012-current

Member, UAHN Strategic Champions, 2009-current

Member and Chair, DRC Clinical Research Task Force, 2010-current

Member, Biochemistry & Molecular and Cellular Biology Graduate Program, 2009-present

Member, Arizona Cancer Center Undergraduate Continuing Umbrella of Research Experiences (CURE) program, 2007-present

Member, College of Medicine Executive Council, 2006-present

Member, University of Arizona College of Medicine Phoenix Steering Committee, 2004-2007

Member, College of Medicine Dean's Council, 2004-present

Member, University of Arizona Bioinstrumentation Committee, 2003-present

Member, Dean's Research Council Space Committee, 2003-present

Chair, Dean's Research Council, 2003-present

Chair, Cancer Biology T32 Trainee Selection, 1996-2005

Member, Cancer Biology Graduate Interdisciplinary Program, 1988-2005

Member, University of Arizona Cancer Center, 1986-present

Arizona Cancer Center Faculty Mentor:

Jonathan Walker, M.D., Dept. of Surgery, 2006-2007.

Terry Landowski, Ph.D., Dept. of Medicine, 2006-present.

George Watts, Ph.D., Dept. of Pharmacology, 2007-2009.

Previous service:

Member, University of Arizona Search Committee; Provost, 2007

Member, College of Medicine Search Committee; Chair, Department of Surgery, 2003-2006

Member, Institute for Biomedical Science and Biotechnology Scientific Advisory Board, 2003-2006

Member, Executive Committee, Arizona Cancer Center, 1998-2006

Member, Search committee, Chair, Dept of Medicine, University of Arizona College of Medicine, 2006

Member, Search committee, Vice Dean, University of Arizona College of Medicine, Phoenix, 2006

Member, Cell Biology and Anatomy Faculty Development Committee, 2005

Member, Fostering Scientific Careers of Women Committee, 2005

Member, Search Committee, Associate Vice President for Federal Relations, 2005

Member, Executive Committee, Advanced Research Institute for Biomedical Imaging, 2005.

Member, Vice President for Research, Graduate Studies and Economic Development, search committee 2005

Member, Arizona Cancer Center Director's Committee, 2005

Member, ADCRC-Flinn Translational Research Project, 2004

Member, Arizona Cancer Center Director Search Committee, 2004

Member, College of Medicine Search Committee; Dean, College of Medicine 2003

Member, University of Arizona Focused Excellence Life Sciences Study Team, 2003

Chair, Medical Research Building Planning Committee, 2002-2004

Director, Arizona Cancer Center Cancer Metastasis and Signaling Program, 2000-2006

Member, Joint Arizona Cancer Center and Molecular and Cellular Biology Search Committee, 2000

Member, Radiation Oncology Search Committee, Physicist, 1999

Committee Chair, American Cancer Society Institutional Grants (IRG), 1999-2003

Chair, Radiation Oncology Departmental Promotion and Tenure Committee, 1999-2002

Member, Dean's Research Council Space Committee, 1999-2002

Member, Dean's Research Council, College of Medicine, 1999-2002

Member, Arizona Cancer Center Director Search Committee, 1998-99

Interviewer, Medical School Admissions Committee, 1998-99

Member, Continuing Medical Education Committee, 1991-96

Reviewer, American Cancer Society Institutional Grants (ICRG), 1997-99

Lecturer, Prostate Cancer Support Group, 1998

Member, DNA Microarray Research Group, 1998-99

Member, Cancer Biology Student Progress Committee, 1996-98

Member, Cancer Biology Executive Committee, 1994-2005

Member, Biomedical Implant and Wound Healing Program, Department of Surgery, 1996

Presenter and judge, St. Gregory College Preparatory School Science Fair, March, 1995

Participant, University of Arizona "WALK, DON'T RUN, The Migration of a Cancer Cell", University Medical Center, January, 1995

Cancer Center Executive Committee Member, 1989-1992 (substitute for Dr. Gerner or Dr. Bowden); 1995

Lecturer for tour, Desert View High School, "Molecular Changes in Prostate Cancer Cells", Arizona Cancer Center, May, 1994

Participant, mock site visit for Colon Cancer Prevention Program Project, Arizona Cancer Center, September, 1994

Member, Review Committee for Research Grants from Vice President for Research Office, 1994

Presenter, Salpointe High School, "Introduction to Health Careers", November, 1993

Participant, NCI Construction Site Visit for Arizona Cancer Center, July, 1993

Contributed enduring materials to "Image Processing for Teaching" to Department of Planetary Sciences Lunar and Planetary Laboratory, July, 1993

Lecturer, general biology class, Pima Community College, April 1993

Lecturer, Community Information in Cancer Biology, 1990, 1991, 1992, 1993, Cancer Center

Lecturer, Postgraduate Oncology Core Course, April 1992

Lecturer, Native American Conference on Careers in Cancer Medicine, 1992

Member, Cancer Biology Student Progress Committee, 1991-1993

Lecturer for “Horizons Unlimited” conducted by Office of Instruction on main campus to high school seniors, June, 1991

Lecturer, Mountain View High School, “Importance of Cell Biology and Cancer Research”, January, 1991

Member, Recruitment Committee for Director of Radiation Safety Program, 1991

Lecturer, Cancer Biology Research for Friends of the Cancer Center and Kiwanis Club

Lecturer, High School, “Importance of Science in Cancer Prevention, Treatment and Diagnosis”

Lecturer, Parents Day Tours of Cancer Biology Laboratories, 1989, 1990, 1991

Lecturer, Undergraduate Biology Research Program, Cancer Biology

Lecturer, Cancer Center Run Science Booth for community awareness of Cancer Biology Research

Member, Review of Medical Biochemistry Teaching, 1991

Lecturer, Science Career Day at University of Arizona, 1991

Member, Medical Student Admission Committee, College of Medicine, 1988-1991

Member, Admissions Committee, Cancer Biology Graduate Program, Radiation Oncology Dept., 1988-1991

Cancer Biology Pre and Post-doctoral Selection Committee (substitute), 1989

Reviewer, Grant Proposals, Biomedical Research Support Grants, 1989

Member (Ad Hoc), Cancer Biology Executive Committee, (substitute) 1989

Member, Radiation Oncology Faculty Search Committee, 1988-1989

Member, Honors and Awards Committee, College of Medicine, 1988

Organizer, Radiation Oncology Department Cancer Biology Seminar Series, 1986-1992

Interviewer, Medical School Admissions Committee, 1987-1988

Member, Graduate Student Progress Committee, Microbiology and Immunology Department, 1987-1990

Graduate Student Advisor, Microbiology & Immunology Department, 1987-1989

Reviewer, Flinn Foundation grant applications, 1987, 1988

Member, Medical Student Appeals Committee, College of Medicine, University of Arizona, 1986, 1987

RESEARCH FUNDING:

Current Support:

NIH RO1 CA 195406 (**AE Cress**, PI)
07/26/2011-05/31/2016 \$1,197,920 total direct costs
Human Prostate Cancer Metastasis and Laminin Binding Integrins

NIH RO3CA164484-01 (I Sroka, PI; **AE Cress**, co-PI)
12/01/12-11/30/14 (\$75,750 annual costs)
“Mechanisms of Pancreatic Tumor Nerve Invasion”

DoD, W81XWH-11-PCR (A. Algotar, PI; **AE Cress**, Mentor) 2013-2015
“DNA Damage and Genetic Instability as Harbingers of Prostate Cancer”.

USPHS T32 CA-09213 Cancer Biology Training Grant (G.T. Bowden, PI)
(05/19/08 - 04/30/13)
AE Cress, Participating Faculty, no salary support

Previous Support:

NIH PO1 CA56666-04A1 (RB Nagle, **AE Cress**, co-PI)
04/19/04-03/31/2010 \$607,597 total PPG annual direct cost (no-cost extension)
Prostate Carcinoma: Invasion and Metastasis Factors
Project II-Cellular Adhesion and Prostate Tumor Cell Progression (**AE Cress**, Project Director)

Multiple Myeloma Research Foundation
(01/01/06-12/31/08) \$50,000 direct cost
L Hazlehurst, University of South Florida. **AE Cress**, Co-PI (no salary support)
HYD-1 on Melphalan Sensitivity in Myeloma Model

NIH RO1 CA75152 (**AE Cress**, PI)
04/01/01-03/31/08 \$871,500 total direct costs
Ionizing Radiation Signaling Through the Alpha 6 Beta 4 Integrin

Arizona Cancer Center Basic Science Collaborative Research Pilot Grants
(07/01/06-06/30/07) \$50,000 direct cost
G Watts/ **AE Cress** co-PI
Integrin-Cyr61 Interaction in Esophageal Adenocarcinoma Tumor Cell Migration

NIH P30 CA 23074 (D. Alberts, PI)
Cancer Center Support Grant
Director, Cancer Metastasis and Signaling Program

NIH R13 CA110912 (**AE Cress**, PI)
05/01/2004-04/30/2005 \$5,000
Therapeutic Targeting of Human Prostate Cancer Conference

NIH CA 81886 (F. Meyskens, PI)
Chemoprevention of Familial Prostate Cancer
Project 2: SEBs in Prostate Cancer Chemoprevention (**E. Gerner**, PI)
\$851,414 total direct costs \$159,125 annual direct project costs

NIH RO1 CA75152 (**Cress**, PI)
04/01/98-03/31/01 \$666,507 total direct costs

Ionizing Radiation Signaling Through the Alpha 6 Beta 4 Integrin

ACS Institutional Research Grant (**A.E. Cress, PI**, grant administrator)
07/01/98-10/01/03 \$240,000 total direct costs

ADCRC (**Cress, PI**)
07/01/98-06/30/01 \$150,000 total costs
Targeting of Lung Cancer Cells with Anti-Adhesive Agents

ADCRC (Nagle PI, **Cress** and Williams Co-PI)
07/01/98-06/30/01 \$146,559 total costs
Improved Extracellular Matrix for Treatment of Tobacco Related Occlusive Vascular Disease

USPHS Grant 2 P01 CA-56666-OIAI
Prostate Program Project Grant (R. B. Nagle, M.D., PI)
Project II-Cellular Adhesion and Prostate Tumor Cell Progression
A.E. Cress, Ph.D., Project Director
\$1,232,902 total direct costs (04/01/93 - 03/31/98)

DOE Grant DE-FG03-93ER61595-A000
The Accessibility of Chromatin as a Biological Dosimeter for DNA Damage by Ionizing Radiation
(**A.E. Cress, PI**) \$405,000 total direct costs (05/01/93 - 04/30/96).

USPHS Grant P01 CA-17094 (S. Salmon, M.D., PI)
Medical Oncology Program Project Grant
Project II-Pharmacology (D. Alberts, M.D., Project Director) (12/01/88 -11/30/93)

USPHS T32 CA-09213 Cancer Biology Training Grant (E.W. Gerner, PI)
\$734,252 total direct costs (09/01/83 - 08/31/93) Participating Faculty

USPHS Grant T32 CA-09213 Cancer Biology Training Grant (E.W. Gerner, PI)
(09/01/78-08/31/79) Postdoctoral Training Position

NIH 839263 (**A.E. Cress, PI**)
Biomedical Research Support Grant
\$4,920 total direct costs (09/18/81-09/17/82)

USPHS Grant CA-31010 (**A.E. Cress, PI**)
DNA Protein Crosslinks After Hyperthermia and Radiation
07/01/81 - 06/30/84
\$117,140 total direct costs

USPHS Grant CA-31010 (**A.E. Cress, PI**)
DNA Protein Crosslinks After Hyperthermia and Radiation
07/01/84 -06/30/88
\$348,279 total direct costs

USPHS Grant CA-30052 (E.W. Gerner, PI)
AE Cress, Director, Project 2
Biochemical & Cellular Aspects of Hyperthermic Damage

\$542,001 total direct costs (07/01/81 - 06/30/86)

#2SO7 RRO5675-20 University of Arizona College of Medicine Biomedical Research Support Grant
Resistance
\$4,878 total costs (07/01/88-06/30/89)

USPHS Grant P01 CA-17094 (S. Salmon, M.D., PI) Medical Oncology Program Project Grant Project II -
Pharmacology Project
(D. Alberts, M.D., Project Director) \$1,097,616 Total Direct Costs (12/01/83 - 11/30/88)
\$257,146 Total Direct Costs Project II (December 1, 1983 to November 30, 1988) Co-Investigator

USPHS Grant 1 P01 CA-17343 (E.W. Gerner, PI)
Heat, Radiation and Drugs in Cancer Therapy
\$1,642,128 total direct costs (07/01/86 - 06/30/91) **AE Cress, Project Director**, Project 2

American Cancer Society Grant, #CH-467 (**A.E. Cress**, PI)
Intracellular Protein Binding of Chemotherapeutic Drugs.
\$204,186 total costs (07/01/89 - 06/30/91).

Phoenix Friends of the Arizona Cancer Center (**A.E. Cress** and J.A. Majda, M.D. co-PI)
Integrin Expression in Human Breast Carcinoma
Total costs: \$20,000, (02/01/91-01/30/92)

SCIENTIFIC REVIEWS

Special Emphasis Panel, NCI-ARRA Grant Opportunities – Stem Cells/Cell Biology, August 2009.

Chair, Tumor Progression and Metastasis NIH Study Section, 2009-2011, Member, 2004-2008

Invited External Reviewer, Tumor Microenvironment Extracellular Matrix U54, Fred Hutchinson Cancer
Center, University of Washington, Seattle, WA, 2008

Member, Special Emphasis Panel, Cancer Center Support Grant, Memorial-Sloan Kettering Cancer Institute,
New York 5/2007.

Molecular Oncology Program Project, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL,
consultant, 2003-2005

American Association for Cancer Research Grants Committee, 2004-2005

Cell Biology Study Section, American Cancer Society, 1995 to 2000 (Member), 2000-2001 (Chair)

Member, Radiation Research Study Section, NIH, 1997-2004

Radiation Research Society, Member, Policies and Issues Committee, 1997-2000

Review of Department of Defense Research Awards, 1995

Site Visit Reviewer, Program Project Grants, National Institutes of Health. Sites: M.D. Anderson Hospital, Houston and The University of Chicago. 1981, 1988; Moffitt Cancer Center, Tampa, FL, 1999.

Manuscript review:

Biochemistry Journal	Molecular Carcinogenesis
Cancer Cell	Nature
Cancer Research	Neoplasia
Carcinogenesis	PLoS Medicine
Cell and Molecular Biology	Prostate
Clinical and Experimental Metastasis	Radiation Research
Experimental Cell Research	Science
International Journal of Radiation Biology	The Open Prostate Cancer Journal, Associate Editor
Journal of Biological Chemistry	Translational Oncology
Journal of Cell Biology	American Journal of Translational Research, Senior Editorial Board Member
Journal of Cell Science	
Journal of Cellular Biochemistry	

PUBLICATIONS (Refereed Journal Articles, most recent listed first):.

98. Sukhtankar D, Okun A, Chandramouli A, Nelson MA, Vanderah TW, **Cress AE**, Porreca F, King T. Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain. *Mol Pain*. 2011 Oct 20;7:81.
97. Emmons MF, Gebhard AW, Nair RR, Baz R, McLaughlin ML, **Cress AE**, Hazlehurst LA. Acquisition of resistance toward HYD1 correlates with a reduction in cleaved $\alpha 4$ integrin expression and a compromised CAM-DR phenotype. *Mol Cancer Ther*. 2011 Dec, 10 (12):2257-66.
96. Nagle RB, **Cress AE**. Metastasis Update: Human Prostate Carcinoma Invasion via Tubulogenesis. *Prostate Cancer*. 2011;2011:249290.
95. Isis C. Sroka, Cynthia P. Sandoval, Jaime M. Gard, Harsharon Chopra, Sangita C. Pawar, **Anne E. Cress**. Macrophage Dependent Cleavage of the laminin receptor $\alpha 6 \beta 1$ in Prostate Cancer. *Molecular Cancer Research*, 9: 1319-1328, 2011.
94. Isis C. Sroka, Todd Anderson, Kathy McDaniel, Raymond B. Nagle, Matthew B. Gretzer, **Cress AE**, The Laminin Binding Integrin $\alpha 6 \beta 1$ in Prostate Cancer Perineural Invasion. *J Cell Physiol*, 224:283-288, 2010.
93. Vrba L, Jensen TJ, Garbe JC, Heimark RL, **Cress AE**, Dickinson S, Stampfer MR and Futscher BW. Role for DNA Methylation in the Regulation of miR-200c and miR-141 Expression in Normal and Cancer Cells. *PLOS One* 2009.
92. Nair RR, Emmons MF, **Cress AE**, Argilagos RF, Lam K, Kerr WT, Wang H-G, Dalton WS, Hazlehurst LA. HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells. *Mol Cancer Ther* 2009;8(8):2441-51.
91. Ports M, Nagle RB, Pond G, **Cress AE**. Extracellular engagement of alpha 6 integrin inhibited urokinase-type plasminogen activator-mediated mediated cleavage and delayed human prostate bone metastasis. *Cancer Research* 69(12) 5007-14, 2009

90. Warters RL, Gaffney DK, Kramer GF, Martinez JD, **Cress AE**. Transient Dephosphorylation of p53 Serine 376 as an Early Response to Ionizing Radiation. Radiation Research 171:725-34, 2009.
89. Sroka IC, Pond, GD, Nagle RB, Porreca F, King, T, Pestano G, Futscher BW, Gard, JM, Riley, J and **Cress AE**. Molecular imaging candidates identified in metastatic human prostate cancer cells in a xenograft model. Open Prostate Cancer Journal 2: 1876-1880, 2009.
88. King TE, Pawar SC, Majuta L, Sroka IC, Wynn D, Demetriou MC, Nagle RB, Porreca F, **Cress AE**. The role of Alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model. PLOS One, (3)10: 3535, 2008.
87. Sroka IC, Chen ML and **Cress AE**. Simplified purification procedure of laminin-332 and laminin-511 from human cell lines. Biochemical and Biophysical Research Communications 375: 410-413, 2008.
86. Demetriou MC, Kwei KA, Powell MB, Nagle RB, Bowden GT, **Cress AE**. Integrin A6 cleavage in mouse skin tumors. The Open Cancer Journal 2:1-4, 2008.
85. Demetriou MC, Stylianou P, Andreou M, Yiannikouri O, Tsaprialis G, **Cress AE**, Skourides P. Spatially and temporally regulated A6 integrin cleavage during *Xenopus laevis* development. Biochemical and Biophysical Research Communications, 366(3):779-85, 2008.
84. King T, Vardanyan A, Majuta L, Melemedjian O, Nagle R, **Cress AE**, Vanderah TW, Lai, J, Porreca F. Morphine treatment accelerates sarcoma-induced bone pain, bone loss and spontaneous fracture in a murine model of bone cancer. Pain 132(1-2):154-68, 2007.
83. Pawar SC, Dougherty S, Pennington ME, Demetriou MC, Stea BD, Dorr RT and **Cress AE**. A6 Integrin Cleavage: Sensitizing Human Prostate Cancer to Ionizing Radiation. Int J Radiat Biol. 2007 Nov;83(11):761-7
82. Pawar SC, Demetriou MC, Nagle RB, Bowden GT, **Cress AE**. Integrin A6 cleavage: A novel modification to modulate cell migration. Exp. Cell Research 313:1080-1089, 2007.
81. Sroka TC, Marik J, Pennington ME, Lam K and **Cress AE**. The minimum element of a synthetic peptide required to block prostate tumor cell migration. Cancer Biology and Therapy, 5:11, 1156-1562, 2006.
80. Sroka TC, Pennington ME and **Cress AE**. Synthetic D-amino acid peptide inhibits tumor cell motility on laminin-5. Carcinogenesis, 27:9:1748-1757, 2006.
79. Kremer CL, Schmelz, M and **Cress AE**. Integrin-dependent amplification of the G2 arrest induced by ionizing radiation. Prostate, 66:88-96, 2006.
78. Oshiro MM, Futscher, BW, Lisberg A, Wozniak RJ, Klimecki WT, Domann FE, **Cress AE**. Epigenetic Regulation of the Cell Type-Specific Gene 14-3-3sigma. Neoplasia 7:799-808, 2005.
77. Oshiro M, Kim CJ, Wozniak RJ, Junk DJ, Munoz-Rodriguez JL, Burr JA, Fitzgerald M, Pawar SC, **Cress AE**, Domann FE, Futscher, BW. Epigenetic silencing of DSC3 is a common event in human breast cancer. Breast Cancer Research R669-R680, 2005.
76. Schmelz M, Moll R, Hesse U, Prasad AR, Gandolfi JA, Hasan SR, Bartholdi M, **Cress AE**. Identification of a stem cell candidate in the normal prostate gland. Eur. J. Cell Biology, 84:341-354, 2005.

75. Bair EL, Chen ML, McDaniel K, Sekiguchi K, **Cress AE**, Nagle RG, Bowden GT. Membrane type 1 matrix metalloproteinase cleaves laminin-10 and promotes prostate cancer cell migration. Neoplasia, 7:4:380-389.
74. **Cress AE** and Mohla S. Therapeutic Targeting of Prostate Cancer. Meeting report. Cancer Biology & Therapy, 3(10):1028-30, 2004.
73. Demetriou MC, Pennington ME, Nagle RB and **Cress AE**. Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer. Experimental Cell Research, 294:550-558, 2004.
72. Demetriou MC and **Cress AE**. Integrin clipping: A novel adhesion switch? J. Cellular Biochem, 91:26-35, 2004
71. Chauhan S, Kunz S, Davis K, Roberts J, Martin G, Demetriou MC, Sroka TC, **Cress AE**, Miesfeld RL. Androgen control of cell proliferation and cytoskeletal reorganization in human fibrosarcoma cells: role of RhoB signaling. J. Biological Chem. 279(2):937-944, 2004.
70. Chauhan S, Pandey R, Way JF, Sroka TC, Demetriou MC, Kunz S, **Cress AE**, Mount DW and Miesfeld RL. Androgen regulation of the human FERM domain encoding gene EHM2 in a cell model of steroid-induced differentiation. Biochem Biophys Res Commun, 310: 421-432, 2003.
69. Udayakumar TS, Chen ML, Bair EL, **Cress AE**, Nagle RB and Bowden GT. MT1-MMP expressed by prostate carcinoma cells cleaves human laminin-5 $\beta 3$ chain and induces cell migration. Cancer Research, 63(9):2292-9, 2003.
68. Parrish AR, Sallam K, Nyman DW, Orozco J, **Cress AE**, Dalkin BL, Nagle RB and Gandolfi AJ. Culturing precision-cut human prostate slices as an *in vitro* model of prostate pathobiology. Cell Biology and Toxicology 18:205-219, 2002.
67. Davis TL, Buerger F and **Cress AE**. Differential regulation of a novel variant of the $\alpha 6$ integrin, $\alpha 6p$. Cell Growth and Differentiation, 13:107-133, 2002.
66. Schmelz M, **Cress AE**, Scott KM, Burger F, Cui H, Sallam S, McDaniel K, Dalkin BL, Nagle RB. Different phenotypes in human prostate cancer: $\alpha 6$ or $\alpha 3$ integrin in cell-extracellular adhesion sites. Neoplasia, 4(2):243-254, 2002.
65. Whitacre DC, Chahuan S, Davis TD, **Cress AE**, Miesfeld RL. Androgen-induction of *in vitro* prostate cell differentiation, Cell Growth and Diff.13(1):1-11, 2002.
64. Bair EL, Tran N, Massey CP, Borchers AH, Heimark RL, **Cress AE**, Bowden GT. Integrin and cadherin mediated induction of the matrix metalloprotease matrilysin in co-cultures of malignant oral squamous cell carcinoma cells and dermal fibroblasts. Experimental Cell Research 270:259-267, 2001.
63. Calaluce R, Kunkel MW, Watts GS, Schmelz M, Hao J, Barrera J, Gleason-Guzman M, Isett R, Fitchum M, Bowden GT, **Cress AE**, Futscher BW, Nagle RB. Laminin-5-mediated gene expression in human prostate carcinoma cells. Molecular Carcinogenesis 30:119-129, 2001.
61. Davis TL, **Cress AE**, Dalkin BL, Nagle RB. Unique expression pattern of the $\alpha 6\beta 4$ integrin and laminin 5 in human prostate carcinoma. The Prostate, 46:240-248, 2001.
62. Schmelz M, **Cress AE** and Nagle RB. PEAZ-1: A new human prostate neoplastic epithelial cell line. The Prostate, 48:78-92, 2001.

60. DeRoock IB, Pennington ME, Sroka TC, Lam KS, Bowden GT, Bair EI, **Cress AE**. Synthetic peptides inhibit adhesion of human tumor cells to extracellular matrix proteins. Cancer Research, 61:3308-3318, 2001.
59. Davis TL, Rabinovitz I, Futscher BW, **Cress AE**. Identification of a novel structural variant of the $\alpha 6$ integrin. J. Biol. Chem., 276:(28)26099-26106, 2001.
58. **Cress, AE**. Quantitation of phosphotyrosine signals in human prostate cell adhesion sites. BioTechniques, 29:4:776-781, 2000.
57. Witkowski CM, Bowden GT, Nagle RB, **Cress AE**. Altered surface expression and increased turnover of the $\alpha 6 \beta 4$ integrin in an undifferentiated carcinoma. Carcinogenesis, 21:325-330, 2000.
56. Damiano JS, **Cress AE**, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): Role of $\beta 1$ integrins and resistance to apoptosis in human myeloma cell lines. Blood, 93:1658-1667, 1999.
55. Tran NL, Nagle RB, **Cress AE**, Heimark RL. N-cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion with stromal cells. Am. J. Pathology, 155:787-798, 1999.
54. Hazlehurst LA, Foley NF, Guzman-Gleason MC, **Cress AE**, Hacker MP, Greenberger LW, de Jong MC, Dalton WS. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res. 59:1021-1028, 1999.
53. Martinez JD, Pennington ME, Warters RL and **Cress AE**. Free radicals generated by ionizing radiation signal nuclear translocation of p53. Cell Growth & Diff., 8:941-949 1997.
52. **Cress AE.**, EMBO J. 15: Cover photograph, 1996.
51. von Bredow DC, **Cress AE**, Howard EW and Bowden GT. Activation of gelatinase/tissue inhibitors of metalloproteinase complexes by matrilysin. Biochem J. 331:965-972.
50. von Bredow DC, Nagle RB, Bowden GT and **Cress AE**. Cleavage of $\beta 4$ integrin by matrilysin. Exp. Cell Res., 236:341-345, 1997.
49. McCandless JR, **Cress AE**, Rabinovitz I, Payne CM, Bowden GT, Knox JD and Nagle RB. A human xenograft model for testing early events of epithelial neoplastic invasion. Int. J. Onc. 10:279-285, 1997.
48. **Cress AE** and Dalton WS. Multiple drug resistance and intermediate filaments. Cancer Metastasis Reviews 15:499-506, 1996.
47. Pennington ME, Lam KS and **Cress AE**. The use of a combinatorial library method to isolate human tumor cell adhesion peptides. Molecular Diversity, 2:19-28, 1996.
46. **Cress AE** and Dalton WS. Multiple drug resistance and intermediate filaments. Cancer Metastasis Rev., 15: 499-506, 1996.
45. Abbaszagegan M, **Cress AE**, Futscher BW, Bellamy WT and Dalton WS. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers. Cancer Res., 56:5435-5443, 1996.
44. Hao J, Yang Y, McDaniel KM, Dalkin BL, **Cress AE** and Nagle RB. Differential expression of laminin 5 ($\alpha 3 \beta 3 \gamma 2$) by human malignant and normal prostate. Am. J. Path., 149:4:1341-1349, 1996.

43. Anderson JM, Bauman PA, Ludi CW, Dalton WS and **Cress AE**. Cytokeratin expression results in a drug resistant phenotype to six different chemotherapeutic agents. Clin. Cancer Res. **2**:97-105, 1995.
42. Rabinovitz I, Nagle RB and **Cress AE**. Integrin $\alpha 6$ expression in human prostate carcinoma is associated with a migratory and invasive phenotype *in vitro* and *in vivo*. Clin. Exp. Metastasis. **13**:481-491, 1995.
41. **Cress AE**, Rabinovitz I, Zhu W and Nagle RB. The $\alpha 6 \beta 1$ and $\alpha 6 \beta 4$ integrins in human prostate cancer progression. Cancer and Metast. Rev., **14**:219-228, 1995.
40. von Bredow DC, Nagle RB, Bowden GT and **Cress AE**. Degradation of fibronectin fibrils by matrilysin and characterization of the degradation products. Exp. Cell Res. **221**:83-91, 1995.
39. Nagle RB, Hao J, Knox JD, Dalkin BL, Clark V and **Cress AE**. Expression of hemidesmosomal and extracellular matrix proteins by normal and malignant human prostate tissue. Am. J. Pathol. **146**:1498-1507, 1995.
38. Nagle RB, Knox JD, Wolf C, Bowden GT and **Cress AE**. Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma. J. Cell Biochem. Suppl. **19**:232-237, 1994.
37. Wallon UM, Shassetz LR, **Cress AE**, Bowden GT and Gerner EW. Polyamine-dependent expression of the matrix metalloproteinase matrilysin in a human colon cancer-derived cell line. Mol. Carcinogenesis. **11**(3):138-144, 1994.
36. Makar R, Mason A, Kittelson JM, Bowden GT, **Cress AE** and Nagle RB. Immunohistochemical analysis of cathepsin D in prostate carcinoma. Mod. Pathol. **7**(7):747-751, 1994.
35. Knox JD, **Cress AE**, Clark V, Manriquez L, Affinito KS, Dalkin BL and Nagle RB. Differential expression of extracellular matrix molecules and the $\alpha 6$ integrins in the normal and neoplastic prostate. Am. J. Pathol. **145**(1):167-174, 1994.
34. Bauman PA, Dalton WS, Anderson JM and **Cress AE**. Expression of cytokeratin confers multiple drug resistance. Proc. Natl. Acad. Sci. USA, **91**(12):5311-5314, 1994.
33. Rabinovitz I, **Cress AE** and Nagle RB. Biosynthesis and secretion of laminin and S-laminin by human prostate carcinoma cell lines. Prostate, **25**:97-107, 1994.
32. Majda J, Gerner EW, Vanlandingham B, Gehlsen KR and **Cress AE**. Heat shock-induced shedding of cell surface integrins in A549 human lung tumor cells in culture. Exp. Cell Res., **210**:46-51, 1993.
31. Witkowski C, Rabinovitz I, Nagle RB, Affinito KS and **Cress AE**. Characterization of integrin subunits, cellular adhesion and tumorigenicity of four human prostate cell lines. J. Cancer Res. Clin. Oncol., **119**:637-644, 1993.
30. Peck VM, Gerner EW and **Cress AE**. A DNA polymerase alpha associated 56kDa protein kinase activity which phosphorylates DNA polymerase a associated peptides. Biochem. Biophys. Res. Commun., **190**:325-331, 1993.
29. Nagle RB, Petein M, Brawer M, Bowden GT and **Cress AE**. New relationships between prostatic intraepithelial neoplasia and prostatic carcinoma. J. Cell Biochem. **16H**:26-29, 1992.
28. Peck VM, Gerner EW and **Cress AE**. Delta type DNA polymerase characterized from *Drosophila melanogaster* embryos. Nucleic Acids Res. **20**:5779-5784, 1992.
27. Vernetti LA, Sarid D, Gandolfi AJ, Nagle RB, Hameroff S, McCuskey R and **Cress AE**. The topographical structure of cytokeratin intermediate filaments using scanning tunneling microscopy. Nanobiology **1**:379-386, 1992.

26. Short WO, Goodwill L, Taylor CW, Job C, Arthur ME and **Cress AE**. Alteration of human tumor cell adhesion by high strength static magnetic fields., Invest. Radiol., p. 836-840, 1992.
25. Seftor REB, Seftor EA, **Cress AE** and Hendrix MJC. Profiles of human melanoma cell surface proteins:effects of culturing on two different substrates. Pigment Cell Res. **3**:44-48, 1990.
24. **Cress AE**, Majda JA, Glass JR, Stringer DE and Gerner EW. Alteration of cellular adhesion by heat shock. Exp. Cell Res. **190**:40-46, 1990.
23. **Cress AE**, Kurath KM, Stea B and Bowden GT. The crosslinking of nuclear proteins to DNA using ionizing radiation. Cancer Res. Clin. Oncol. **116**:324-330 1990.
22. Ostrowski LE, Krieg P, Finch J, **Cress AE**, Nagle RB and Bowden GT. Expression of b-actin during progression of mouse skin tumors. Carcinogenesis **10**:1439-1444, 1989.
21. Roberts RA, **Cress AE** and Dalton WS. Persistent intracellular binding of mitoxantrone in a human colon carcinoma cell line. Biochem. Pharm. **38**:4283-4290, 1989.
20. Bonham K, Embry T, Gibson D, Jaffe DR, Roberts RA, **Cress AE** and Bowden GT. Activation of the cellular harvey ras gene in mouse skin tumors initiated with urethane. Mol. Carcinogenesis **2**:34-39, 1989.
19. **Cress AE**, Kurath KM, Hendrix MJC and Bowden GT. Nuclear protein organization and the repair of radiation damage. Carcinogenesis **10**:939-943, 1989.
18. **Cress AE** and Kurath KM. Identification of attachment proteins for DNA in Chinese hamster ovary cells. J. Biol. Chem. **263**:19678-19683, 1988.
17. **Cress AE**, Roberts RA, Bowden GT and Dalton WS. Modification of keratin by the chemotherapeutic drug mitoxantrone. Biochem. Pharm. **37**:3043-3046, 1988.
16. Dalton WS, **Cress AE**, Alberts DS and Trent JM. Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Res. **48**:1882-1888, 1988.
15. Yamanishi DT, Bowden GT and **Cress AE**. An analysis of DNA replication in synchronized CHO cells treated with benzo[a]pyrene diol epoxide. Biochimica et Biophysica Acta **910**:34-42, 1987.
14. Dalton W, Durie B, Alberts D, Gerlach JH and **Cress AE**. Characterization of a new drug resistant human myeloma cell line which expresses P-glycoprotein. Cancer Res. **46**:5125-5130, 1986.
13. Glass JG, DeWitt RG and **Cress AE**. Rapid loss of stress fibers in Chinese hamster ovary cells after hyperthermia. Cancer Res. **44**:258-262, 1985.
12. **Cress AE** and Bowden GT. Covalent DNA-protein crosslinking occurs after hyperthermia an radiation. Radiat. Res. **95**: 610-619, 1983.
11. Davis RC, Bowden GT and **Cress AE**. The effect of heat and radiation on the initiation and elongation processes of DNA synthesis. Int. J. Radiat. Biol. **43**:379-390, 1983.
10. **Cress AE**, Culver PS and Gerner EW. The correlation between amounts of cellular membrane components and sensitivity to hyperthermia in a variety of mammalian cell lines in culture. Cancer Res. **42**:1716-1721, 1982.
9. Bowden GT, Kasunic M and **Cress AE**. Thermal enhancement of x-ray induced DNA crosslinking. Radiat. Res. **89**:203-208, 1982.
8. Herman TS, **Cress AE**, Sweets CC and Gerner EW. Reversal of resistance to methotrexate by hyperthermia in chinese hamster ovary cells. Cancer Res. **41**:3840-3843, 1981.

7. **Cress AE** and Bowden GT pH stepwise alkaline elution of DNA replication intermediates during S phase. Biochem. Biophys. Res. Commun. **102**:845-853, 1981.
6. **Cress AE** and Gerner EW. Ornithine decarboxylase induction in cells stimulated to proliferate differs from that in continuously dividing cells. Biochem. J. **188**:375-380, 1980. PMC1161879
5. Gerner EW, **Cress AE**, Stickney DG, Holmes DK and Culver PS. Factors regulating membrane permeability alter thermal resistance. Ann. N.Y. Acad. Sci. **335**:215-235, 1980.
4. **Cress AE** and Gerner EW. Cholesterol levels inversely reflect the thermal sensitivity of mammalian cells in culture. Nature **283**:677-679, 1980.
3. **Cress AE** and Gerner EW. Hydroxyurea effects ODC induction, but not the G1 to S phase transition. Biochem. Biophys. Res. Commun. **87**:773-780, 1979.
2. Herman TS, **Cress AE** and Gerner EW. Collateral sensitivity to methotrexate in cells resistant to adriamycin. Cancer Res. **39**:1937-1942, 1979.
1. **Cress AE** and Gerner EW. Hydroxyurea treatment affects the G1 phase in next generation CHO cells. Exp. Cell Res. **110**:347-353, 1977.

PUBLICATIONS: (Submitted/Planned)

7. Isis C. Sroka, Sangita C. Pawar, Jaime M. Gard, Cynthia P. Sandoval, Harsharon Chopra, **Anne E. Cress**. Characterization of Laminin Binding Integrins and the uPA/uPAR Axis in Human Prostate Tumor cell Lines, *Exp Cell Res*, 2012.
6. Christopher P. Geffre, Gerald D. Pond, Isis C. Sroka, Sangita Pawar, Jamie M. Gard, Bethany A. Skovan, William E. Meek, Bradley E. Bowman, Justin J. Jeffery, Terry H. Landowski, Raymond B. Nagle and **Anne E. Cress**. Rapid evaluation of skeletal metastasis in live animals by microCT, image matched histopathology and the retrieval of metastatic cells. *PLOS One*, 2012
5. Laminin receptor internalization, recycling and invasion of human prostate and breast cancer cells, Todd A. Anderson, Jaime Gard, Isis C. Sroka, Stephanie Strautman, Colm Morrissey, Beatrice Knudsen and **Anne E. Cress** (Submit to *JBC*)
4. Bone metastasis progression blocked by altering laminin binding integrin function, Christopher Geffre, Gerald Pond, Jaime Gard and **Anne E. Cress** (Submit to *Mol Cancer Therapeutics*)
3. Novel inside-out regulation of laminin binding integrin function, Apollo Kascinta, Isis Sroka, Joshua Gordon, Todd Anderson, Cynthia Sandoval and **Anne E. Cress** (Submit to *JBC*)
2. Residual DNA damage: a consequence of the invasive tumor phenotype. Erika Pond, Thomas C. Sroka, Terry Landowski, Jaime M. Gard, Ray B. Nagle and **Anne E. Cress** (Submit to *MCT*)
1. Schwann Cells Promote Tumor Cell Invasion through regulation of the laminin receptor A6B1 integrin, Harsharon Chopra, Zyanya P. Espinosa Riquer, **Anne E. Cress** and Isis C. Sroka (

PUBLICATIONS: Book and Book Chapters

Amit Algotar, Suzanne Stratton and **Anne E. Cress**. New Paradigm for Prostate Cancer Prevention Studies, (Book Chapter, *Cancer Prevention*, 2013)

Davis TL, Goldman AJ and **Cress AE**. Suppression and alteration of adhesion structures in human epithelial cancer progression. In: *Cancer Metastasis – Biology and Treatment* (Springer Publ., AE Cress and RB Nagle Eds.) Vol. 9, p19-46, 2006.

Sroka TC, **Cress AE**, Lam K. Epithelial cell surface targeting using synthetic D-amino acid peptides. In: *Cell Adhesion and Cytoskeletal Molecules in Metastasis*. In: *Cancer Metastasis – Biology and Treatment* (Springer Pub., AE Cress and RB Nagle Eds.) Vol. 9, p179-192, 2006.

Nagle RA, **Cress AE** and Bowden GT. Epithelial stromal relationships in the prostate and their role in prostate tumor progression. In: *Adv. Pathol. Lab. Med.* Vol. 8, pp. 509-522, 1995.

Cress AE, Olson KM and Olson GB. The alteration of chromatin domains during DNA damage repair induced by ionizing radiation. In: *Radiation Damage in DNA: Structure/Function Relationships.*, pp. 419-426, Battelle Press, A.F. Fuciarelli and J.D. Zimbrick (eds.), 1995

ART WORK

EMBO J. 22:4, 2003, cover photograph, **Cress AE** and Pond GD.

EMBO J. 15, 1996, cover photograph, **Cress AE**.

INVENTIONS:

Cress AE, Davis, TL, Rabinovitz I. A6p as a Novel Therapeutic or Diagnostic Agent. 2002

Damiano JS, **Cress AE**, Hazlehurst LA, Shatil A and Dalton W. Compounds and Methods of Modulating Cell-Adhesion Mediated Drug resistance. 2001.

Cress AE and Lam KS. Integrin $\alpha 6$ Adhesion Peptides and Targeting of Prostate Cancer, 1996.

PATENTS:

Dalton WS, Damiano JS, **Cress AE**. Compounds and Methods for Modulating Cell Adhesion-Mediated Drug Resistance, Patent #6,812,003, 2004.

Dalton WS, Damiano JS, **Cress AE**. Compounds and Methods for Modulating Cell Adhesion-Mediated Drug Resistance, Patent #7,253,149, 2007.

Hazlehurst LA, Dalton WS, Cress AE, Lam K. HYD1 peptides as Anti-Cancer Agents. Patent #7,632,814, 2010.

INVITED SCIENTIFIC PRESENTATIONS (Most recent listed first)

Ventana Medical Systems Tucson Symposium 2009, “Laminin Receptors and Adaptive Prostate Cancer Progression”, March 5, 2009.

Karmanos Cancer Institute Grand Rounds, Wayne State University School of Medicine, Detroit, Michigan, “Adaptive Adhesion and Cancer Metastasis” October 30, 2008.

Joint Metastasis Research Society-AACR Conference on Metastasis, “ Extracellular Engagement of alpha 6 Integrin Blocks uPA Mediated Cleavage and Prevents Human Prostate Bone Metastasis”, Vancouver BC, Canada, August 3-7, 2008

FASEB Signal Transduction Through Tetraspanins and Other Multi-Protein Cell Surface Complexes Summer research conference. Presentation: Integrin alpha6 cleavage and lateral membrane associations during human prostate cancer progression, New Haven, CT, June 22-27, 2008.

Radiation and Multidrug Resistance Mediated via the Tumor Microenvironment Workshop. Session Chair: Cell Adhesion-mediated radiation resistance. Presentation: Alpha 6 integrin cleavage: Sensitizing prostate cancer to radiation. Dresden, Germany, February 12-13, 2007.

Cancer Metastasis and Signaling Program, Sixth Arizona Biosciences Leadership Symposium, Phoenix, AZ June 12-13, 2006.

Implementing a Data-Driven Approach to Space Management, American Association of Medical Colleges joint annual meeting, Group on Business Affairs and Group on Institutional Planning, Vancouver, Canada, April 2006.

The $\alpha 6$ Integrin in Human Prostate Cancer Progression, University of British Columbia, Vancouver, April 2006.

Integrin Cleavage and Human Prostate Cancer Progression. Departments of Laboratory Medicine and Pathology, College of Medicine, University of Minnesota, Minneapolis, MN, February 14, 2006.

Human Prostate Cancer Progression and Integrin $\alpha 6 \beta 1$, Philipps – Universitat Marburg, Germany, January 7, 2006.

Human Prostate Cancer Progression and Integrin Cleavage, WCI Emory University, Atlanta, Georgia, April 29, 2005

Integrin Cleavage in Cancer Progression, Montagna Symposium on the Biology of Skin, Oregon, October 15-19, 2004.

Integrin Adhesion Switching: Human Prostate Cancer and Therapeutic Targets. Therapeutic Targeting of Prostate Cancer, Tucson, AZ, May 6-9, 2004.

Human Prostate Cancer and Integrin $\alpha 6 \beta 1$, University of Massachusetts, Boston, MA, November 2, 2004.

Clinical Cancer Biology, Samuel C. Johnson Research Center, Mayo Clinic, Scottsdale, AZ, April, 2000.

Integrins and Translational Research, University of Arizona Medical Research Program, Phoenix Campus, April, 2000.

Integrins and Prostate Cancer, Vancouver Hospital and Health Sciences Center, Vancouver, British Columbia, May, 2000.

Alterations of Integrin Expression in Human Prostate Cancer, Department of Molecular and Cellular Biology, University of Arizona, September, 1999.

Integrins and Cell Adhesion in Prostate Cancer, H. Lee Moffitt Cancer Center, Tampa FL, June, 1999.

Integrins in Prostate Cancer Progression, Dean’s Research Council, College of Medicine, University of Arizona, 1998.

Integrins in Prostate Cancer Progression, Hematology Oncology Research Seminar, Arizona Cancer Center, 1998.

- Integrins in Prostate Cancer Progression, Cancer Biology Seminar Series, Arizona Cancer Center, 1997.
- Integrins and angiogenesis, Surgical Research Semi-Annual Retreat, University of Arizona, 1997.
- Cell adhesion molecules, Blake Conference, Tanque Verde Guest Ranch, Tucson, AZ, 1997.
- Cytokeratin dependent multiple drug resistance, Sunnybrook Health Sciences Center, Toronto, Canada, 1996.
- Integrins in prostate cancer progression, Surgical Ground Rounds, University Arizona Health Sciences Center, 1996.
- Integrins and Prostate Cancer Progression, Medical College of Virginia, Richmond, VA, 1995.
- Human tumor progression and the cytoskeleton, Biochemistry Seminar, Main Campus, 1994.
- Integrin biology and human prostate tumor progression, Biochemistry Seminar, Main Campus, 1993.
- Integrin expression and signaling, Hematology/Oncology Research Conference, Arizona Cancer Center, 1993
- Alteration of human tumor cell adhesion by high strength static magnetic fields. Neurobiology Research Group, Loma Linda, CA, 1992 with Short WS.
- Hyperthermic damage at the molecular level, Invited platform presentation, 38th Annual Meeting of Radiation Research Society, New Orleans, Louisiana, 1990.
- Identification of proteins involved in DNA-protein crosslinks. Platform presentation, 36th Annual Meeting of Radiation Research Society, Philadelphia, PA, 1988.
- Mechanisms of heat resistance. FASEB Research Conference on Mechanisms of Carcinogenesis, Sextons River, Vermont, 1987.
- DNA-protein complexes in eukaryotic cells. Molecular and Cellular Biology Department, University of Arizona, Tucson, Fall 1987.
- Increased level of a proofreading polymerase primase during early embryonic development in *Drosophila melanogaster*. Asilomar Conference, Carmel, California, Fall 1986.
- DNA-protein crosslinking occurs after ionizing radiation. Stanford University, October 1986.
- Nuclear protein organization and the repair of radiation damage. Platform presentation, 34th Annual Meeting of Radiation Research Society, Las Vegas, Nevada, 1986 with Hendrix MJC .
- Nuclear matrix proteins are covalently linked to DNA after ionizing radiation. Symposium presentation, 33rd Annual meeting of the Radiation Research Society, Los Angeles, CA, 1985.
- Radiation induced DNA protein crosslinking. Vanderbilt University, Nashville, Tennessee, 1984.
- Covalent DNA protein crosslinking occurs after ionizing radiation. The Johns Hopkins Oncology Center, Baltimore, Maryland, 1984.
- Production of DNA-protein crosslinks after ionizing radiation. Radiation Oncology Research Laboratory, University of California, San Francisco, 1982.
- Radical scavenger effects on DNA-protein crosslinks. Department of Radiology, University of California, San Diego, 1982.
- Protein synthesis inhibition and the inhibition of DNA replication intermediates. 13th International Cancer Congress, Seattle, 1982 with Gerner, E.W.
- Heat and radiation effects on DNA synthesis mediated by changes in DNA supercoiling. 30th Annual Meeting of the Radiation Research Society, Salt Lake City, 1982 with Davis RC and Bowden GT.

DNA protein crosslinks after hyperthermia and radiation. 30th Annual Meeting of the Radiation Research Society, Salt Lake City, 1982.

Covalent DNA protein complexes occur after DNA damage. American Association of Biological Chemists, St. Louis, 1981 with Bowden GT.

Thermal enhancement of DNA crosslinking induced by radiation damage. ICN-UCLA Symposia, 1981 with Davis RC and Bowden GT.

NATIONAL MEETINGS, Chair:

Initiated, Organized and Co-Chair, "Therapeutic Targeting of Human Prostate Cancer", Tucson, Arizona, May 6-9, 2004. **Cress AE** and Mohla S. Therapeutic Targeting of Prostate Cancer. Meeting report. Cancer Biology & Therapy, 3(10):1028-30, 2004

Chairperson and organizer, Workshop entitled, "Chromatin damage and repair", 38th Annual Meeting of Radiation Research Society, New Orleans, Louisiana, 1990.

Chairperson, "Cellular effects: cytoplasmic and membrane effects of hyperthermia", 10th Annual Meeting of North American Hyperthermia Group, New Orleans, Louisiana, 1990.

Chairperson, "Basic mechanisms", Symposium, 8th Annual Meeting of North American Hyperthermia Group, Philadelphia, PA, 1988.

Chairperson and organizer, Workshop entitled "The formation of DNA-protein crosslinks", 36th Annual Meeting of Radiation Research Society, Philadelphia, PA, 1988.

Chairperson, "Radiation effects on chromosome structure", 34th Annual Meeting of Radiation Research Society, Las Vegas, Nevada, 1986.

Co-chairperson, "Age response of cells to radiation/hyperthermia", 30th Annual Meeting of Radiation Research Society, Salt Lake City, Utah, 1982.

PROFESSIONAL SOCIETIES

National Chemical Honor Society (Iota Sigma Pi)

Radiation Research Society

American Association for the Advancement of Science

American Society for Cell Biology

American Association for Cancer Research

American Society for Matrix Biology